Correlation study of endothelial growth factor receptor transportation with tumor treatment

doi:10.11958/j.issn.0253-9896.2015.08.030

Abstract

Abstract: Abnormal endothelial growth factor receptor transportion was involved in the development of tumor so more and more researches focus it as a target of anti-tumor therapy. Based on the known mechanism in EGFR mis-localization this review summarized the latest research progress in the abnormality in signal of EGFR transportation and its role in tumori⁃ genesis, anti-tumor drug and therapy that target to EGFR. It is aim to provide reference for the development of anti-tumor treatments which target EGFR and for the mechanism in resistance of anti-tumor.

Key words: receptor, epidermal growth factor, signal transduction, oncogenes, antineoplastic protocols, review

References

[1]. Arkhipov A, Shan Y, Kim ET, et al. Membrane interaction of bound ligands contributes to the negative binding cooperativity of the EGF receptor[J].PLoS Comput Biol.2014;10(7):e1003742. [2]. Goh LK, Huang F, Kim W, et al. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor[J].J Cell Biol.2010;189(5):871-83. [3]. Brankatschk B, Wichert SP, Johnson SD, et al. Regulation of the EGF transcriptional response by endocytic sorting[J].Sci Signal.2012;5(215):ra21. [4]. Sousa LP, Lax I, Shen H, et al. Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane[J].Proc Natl Acad Sci U S A.2012;109(12):4419-24. [5].Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer[J].Trends Cell Biol.2014;24(1):26-34. [6]. Lafky JM, Wilken JA, Baron A, et al. Clinical implication of the ErbB/epidermal growth factor(EGF) receptor family and its ligands in ovarian cancer[J].Biochim Biophys Acta.2008;1785(2):232-65. [7]. Lee JC, Vivanco I, Beroukhim R, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain[J].PLoS Med.2006;3(12):e485. [8]. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J].Science.2014;304(5676):1497-500. [9]. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology[J].Nat Rev Cancer.2012;12(8):553-63. [10]. Sorkin A, von Zastrow M. Endocytosis and signaling: intertwining molecular networks[J].Nat Rev Mol Cell Biol.2009;10(9):609-22. [11]. Roepstorff K, Grovdal L, Grandal M, et al. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer[J].Histochem Cell Biol.2008;129(5):563-78. [12]. Shan Y, Eastwood MP, Zhang X, et al. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promoter receptor dimerization[J].Cell.2012;149(4):860-70. [13]. Bublill EM, Pines G, Patel G, et al. Kinase-mediated quasi-dimers of EGFR[J].FASEB J.2010;24(12):4744-55. [14]. Chung BM, Raja SM, Clubb RJ, et al. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src[J].BMC Cell Biol.2009;10:84. [15]. Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer[J]. Trends Cell Biol. 2014 24(1):26-34. [16]. Formisano L, Nappi L, Rosa R, et al. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer[J].Breast Cancer Res.2014;16(3):R45. [17]. Asbagh LA, Vazguez I, Vecchione L, et al. The tyrosine phosphatase PTRRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling[J].Oncotarget.2014.Epub ahead of print. [18]. Res Brewer M, Yun CH, Lai D, et al. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer[J].Pro Natl Acad Sci U S A.2013;110(38):E3595-604. [19]. Faulkner C, Palmer A, Williams H, et al. EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers[J].Br J Neurosurg.2014;20:1-7. [20]. Goh LK, Huang F, Kim W, et al. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor[J].J Cell Biol.2010;189(5):871-83. [21]. Thalappilly S, Soubeyran P, Iovanna JL, et al. VAV2 regulates epidermal growth factor receptor endocytosis and degradation[J].Oncogene.2010;29(17):2528-39. [22]. Mahajan K, Mahajan NP. Shepherding AKT and Androgen receptor by Ack1 tryosine kinase[J].J Cell Physiol.2010;224(2):327-33. [23]. Kelley LC, Weed SA. Cortactin is a substrate of activated Cdc42-associated kinase1(ACK1) during ligand-induced epidermal growth factor receptor downregulation[J].PLoS One.2012;7(8):e44363. [24]. Chua BT, Lim SJ, Tham SC, et al. Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells[J].Mol Oncol.2010;4(4):323-34. [25]. Gao M, Patel R, Ahmad I, et al. SPRY2 loss enhances ErbB trafficking and PI3K/AKT signaling to drive human and mouse prostate carcinogenesis[J].EMBO Mol Med.2012;4(8):776-90. [26]. Galan-Moya EM, de la Cruz-Morcillo MA, LIanos Valero M, et al. Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC[J].PLoS One.2011;6(12):e28406. [27]. Zwang Y, Yarden Y. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy[J].EMBO J.2006;25(18):4195-206. [28]. Roepstorff K, Grandal MV, Henriksen L, et al. Differential effects of EGFR ligands on endocytic sorting of the receptor[J].Traffic.2009;10(8):1115-27. [29]. Markovic A, Chung CH. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma[J].Expert Rev Anticancer Ther.2012;12(9):1149-59. [30]. Kalapurakal SJ, Malone J, Robbins KT, et al. Cetuximab in refractory skin cancer treatment[J].J Cancer.2012;3:257-61. [31]. Nishimura Y, Yoshioka K, Bereczky B, et al. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line[J].Mol Cancer.2008;7:42. [32]. Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy[J].Nutrition.2013;29(1):15-21. [33]. Klomsiri C, Karplus PA, Poole LB. Cysteine-based redox switches in enzymes[J].Antioxid Redox Signal.2011;14(6):1065-77. [34]. Maruyama IN. Mechanisms of activation of receptor tyrosine kinases: monomers or dimmers[J].Cells.2014;3(2):304-30. [35]. Truong TH, Carroll KS. Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation[J].Biochemistry.2012;51(50):9954-65. [36]. Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGFR receptor[J].Oncogene.2006;25(56):7381-90. [37]. Raju U, Riesterer O, Wang ZQ, et al. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways[J].Radiother Oncol.2012;105(2):241-249. [38]. Kim J, Jahng WJ, Di Vizio D, et al.The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus[J]. Cancer Res. 2007 ,67(19):9229-9237. [39]. Wang YN, Wang H, Yamaguchi H, et al. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport[J].Biochem Biophys Res Commun.2010;399(4):498-504. [40]. Du Y, Shen J, Hsu JL, et al. Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking[J].Oncogene.2014;33(6):756-70. [41]. Liao HJ, Carpenter G. Role of the Sec61 translocon inEGF receptor trafficking to the nucleus and gene expression[J].Mol Biol Cell.2007;18(3):1064-72. [42]. Lill NL, Sever NI. Where EGF receptors transmit their signals[J].Sci Signal.2012;5(243):pe41. [43]. Cao X, Zhu H, Ali-Osman F, et al. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis[J].Mol Cancer.2011;10:26.